2023
Chemotherapy-Associated Thrombotic Microangiopathy
Aklilu A, Shirali A. Chemotherapy-Associated Thrombotic Microangiopathy. Kidney360 2023, 4: 409-422. PMID: 36706238, PMCID: PMC10103319, DOI: 10.34067/kid.0000000000000061.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic AgentsGemcitabineHumansNeoplasmsProteasome InhibitorsThrombotic MicroangiopathiesConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyPlasma exchangePrimary atypical hemolytic uremic syndromeAtypical hemolytic uremic syndromeEnd-organ dysfunctionMicroangiopathic hemolytic anemiaSecondary thrombotic microangiopathyTherapeutic plasma exchangeTerminal complement inhibitorLarge multicenter studyHemolytic uremic syndromeRole of complementPotential treatment strategyProteinuria reductionSupportive careBlood pressureMulticenter studyTreatment courseUremic syndromeComplement inhibitionTreatment strategiesHemolytic anemiaAntiangiogenesis agentsComplement inhibitors
2022
Cancer Drug Dosing in Chronic Kidney Disease and Dialysis
Shirali AC, Sprangers B. Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. Advances In Kidney Disease And Health 2022, 29: 208-216.e1. PMID: 35817528, DOI: 10.1053/j.ackd.2021.12.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic AgentsGlomerular Filtration RateHumansKidneyNeoplasmsRenal DialysisRenal Insufficiency, ChronicRenal Replacement TherapyConceptsChronic kidney diseaseKidney diseaseKidney functionEnd-stage kidney diseasePatient's kidney functionRenal replacement therapyCurrent dosing strategiesClassic chemotherapeutic drugsReplacement therapyDosing strategiesHigh prevalenceDrug dosingKidney metabolismAntineoplastic agentsPharmacokinetic propertiesChemotherapeutic drugsDiseaseSpecific agentsPatientsDosingTherapyDrugsAgentsImmunotherapyMalignancy
2016
Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients
Shirali AC, Perazella MA, Gettinger S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. American Journal Of Kidney Diseases 2016, 68: 287-291. PMID: 27113507, DOI: 10.1053/j.ajkd.2016.02.057.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisPD-1 inhibitor therapyInhibitor therapyInterstitial nephritisLung cancerNon-small cell lung cancerAnti-PD-1 antibodyAcute kidney injuryImmune checkpoint inhibitorsT cell immunityCell lung cancerLung cancer patientsClinical trial dataRenal toleranceCheckpoint inhibitorsKidney injuryDeath-1Kidney biopsyCancer patientsPatientsTrial dataTherapyAdverse effectsDrugsNephritis